An Open‐Label Randomized Controlled Trial Comparing the Efficacy and Safety of a 7‐Day Triple Therapy With Bismuth Versus 14‐Day Standard Triple Therapy for Helicobacter pylori Eradication in Children and Adolescents

作者
Anja Šterbenc,Bor Vratanar,Eva Miler Mojškerc,Matjaž Homan
出处
期刊:Helicobacter [Wiley]
卷期号:31 (1): e70103-e70103
标识
DOI:10.1111/hel.70103
摘要

ABSTRACT Background To achieve eradication rates > 90%, the ESPGHAN/NASPGHAN guidelines for pediatric Helicobacter pylori infection recommend tailored antimicrobial therapy using sufficiently high doses over 10–14 days. However, prolonged treatment often leads to suboptimal compliance in children, which is a major contributor to reduced eradication rates. To address this, we evaluated the efficacy and safety of a shorter, 7 day triple therapy with bismuth compared with the 14 day standard triple therapy without bismuth in H. pylori infected children. Materials and Methods From 2020 to 2024, we carried out a randomized controlled trial involving treatment‐naïve children and adolescents (5–18 years old) with confirmed H. pylori infection. Eligible participants were randomly allocated to receive either a 7 day triple therapy with bismuth (bismuth subcitrate, a proton pump inhibitor [PPI], amoxicillin, plus clarithromycin/metronidazole) or a 14 day standard triple therapy (a PPI, amoxicillin, plus clarithromycin/metronidazole) without bismuth. Two months after completing therapy, treatment success was determined using either a two‐step monoclonal stool antigen assay or a urea breath test. Any adverse events were documented using a structured questionnaire. Results Seventy‐three children were enrolled in the study. In the intention‐to‐treat analysis, eradication was achieved in 91% of children treated with the 7 day triple therapy with bismuth and 87% of those receiving the 14 day standard triple therapy ( p = 0.695). Per‐protocol eradication rates were 94% and 87%, respectively ( p = 0.418). No serious adverse events were reported, and most adverse events were mild to moderate. A metallic taste was significantly more frequent in the 14 day standard triple therapy group, while other adverse events occurred with similar frequency. Conclusions Adding bismuth to a 7 day triple regimen achieved high eradication rates and a safety profile similar to 14 day standard triple therapy, supporting its use as an effective and safe treatment option for pediatric H. pylori infection.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
PEI完成签到,获得积分10
刚刚
刚刚
Nana完成签到 ,获得积分10
1秒前
孙浩文发布了新的文献求助10
1秒前
席佳怡发布了新的文献求助10
1秒前
我是老大的应助被YY采纳,获得10
1秒前
JJKK的应助被777采纳,获得10
2秒前
2秒前
2秒前
3秒前
3秒前
zc完成签到 ,获得积分10
3秒前
BENRONG发布了新的文献求助30
4秒前
4秒前
传奇3的应助被晨初采纳,获得10
4秒前
4秒前
5秒前
王乐乐发布了新的文献求助30
5秒前
何文鑫发布了新的文献求助10
6秒前
6秒前
Y123456完成签到,获得积分10
7秒前
乐乐的应助被淡淡的新筠采纳,获得10
7秒前
7秒前
zhang发布了新的文献求助10
7秒前
江子川发布了新的文献求助10
8秒前
9秒前
Owen的应助被z1采纳,获得10
9秒前
9秒前
9秒前
赫江涛发布了新的文献求助10
10秒前
10秒前
cgshao发布了新的文献求助50
11秒前
Frank发布了新的文献求助10
11秒前
小二郎的应助被白华苍松采纳,获得10
11秒前
小浪矢发布了新的文献求助10
11秒前
惔惔惔完成签到,获得积分10
12秒前
江子川发布了新的文献求助10
12秒前
江子川发布了新的文献求助10
12秒前
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Agyptische Geschichte der 21.30. Dynastie 510
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192250
求助须知:如何正确求助?哪些是违规求助? 9578881
关于积分的说明 21862513
捐赠科研通 7791814
什么是DOI,文献DOI怎么找? 3436868
关于科研通互助平台的介绍 2560584
邀请新用户注册赠送积分活动 2483698